Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 8/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17882182 | 0.79 | RIPK1 (0.87) | RIPK1MEN1KMT2AHSD11B1 | |
| SCHEMBL17882290 | 0.79 | RIPK1 (1.00) | RIPK1MEN1KMT2A | |
| SCHEMBL22096075 | 0.77 | RIPK1 (0.63) | RIPK1MEN1KMT2A | |
| SCHEMBL17882203 | 0.76 | RIPK1 (1.00) | RIPK1MEN1KMT2AHSD11B1 | |
| SCHEMBL17882197 | 0.75 | RIPK1 (1.00) | RIPK1MEN1KMT2AHSD11B1 | |
| SCHEMBL29912620 | 0.72 | RIPK1 (0.61) | RIPK1HSD11B1CYP3A4 | |
| SCHEMBL17874096 | 0.72 | RIPK1 (0.61) | RIPK1HSD11B1CYP3A4 | |
| SCHEMBL17882287 | 0.72 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL29046387 | 0.72 | RIPK1 (0.66) | RIPK1MEN1KMT2A | |
| SCHEMBL17882376 | 0.71 | RIPK1 (0.61) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197098-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2023-08-08 | — | — | CN | disclosed |
| CN-115197098-A | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-10-18 | — | — | CN | disclosed |
| CN-107108467-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-08-19 | — | — | CN | disclosed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | disclosed |
| US-10682319-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-16 | — | — | US | disclosed |
| US-10682319-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20200046714-A1 | Treating Male Senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-13 | — | — | US | disclosed |
| US-20180263934-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-09-20 | — | — | US | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| WO-2016101885-A1 | NECROSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682319-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885MEN1 3176/4885KMT2A 4194/4885 |
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | RIPK1 2/4885MEN1 1003/4885KMT2A 2508/4885 |
| US-20200046714-A1 | Treating Male Senescence | RIPK3, RIPK1, MLKL | RIPK1 2/4885MEN1 1003/4885KMT2A 2508/4885 |
| US-20170290790-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885MEN1 3275/4885KMT2A 3654/4885 |
| US-20180263934-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885MEN1 3176/4885KMT2A 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.